World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. More recently developed agents, such as CAR T-cell therapy, may cost almost USD 500,000 annually. Biogen’s failure should be a warning to other pharma companies.

Pharma Companies 210

Pharma Companies Marketing Drugs Production 210

Drug Discovery World

MAY 22, 2023

Ryan Leahy , a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. But are these price tags a barrier to access? million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

Delveinsight

FEBRUARY 9, 2021

Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod. Breyanzi targets CD19, a protein that is highly expressed on the surface of B cells, which remain there following the transformation of these cells from normal to malignant. Ukoniq’s approval was backed by Phase 2 UNITY-NHL Trial (NCT02793583).

FDA Approval 52

FDA Approval Marketing Research Protein 52

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.

Antibody 52

Antibody Medicine Drugs Trials 52

pharmaphorum

JANUARY 11, 2021

While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been delayed by issues with filing data for the FDA. million price tag. The post bluebird bio to split into oncology and gene therapy specialists appeared first on.

Gene Therapy 64

Gene Therapy Gene Genetic Disease Manufacturing 64

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Cell-Based Immunotherapy vs. Immune Biologics. cells, receptors) to treat disease. cells, receptors) to treat disease. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. .

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

pharmaphorum

MARCH 27, 2022

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. In the US, Abecma has a list price of around $420,00, while J&J has set its therapy a little higher at $465,000.

Antibody 98

Antibody Clinical Trials Clinical Trials Sales 98

pharmaphorum

NOVEMBER 16, 2022

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. However, alongside this progress, Ben Hargreaves finds that there is also a conundrum over how to price these therapies.

Gene Therapy 131

Gene Therapy Gene Marketing Development 131

Drug Discovery World

NOVEMBER 13, 2023

Alexander Yermanos, PhD, Lecturer, Systems & Synthetic Immunology, ETH Zurich, on: ‘Integrating single-cell immune repertoire sequencing, machine learning, and biophysical properties of antibodies’. He will discuss selection technologies for membrane targets using advances in whole cell panning and comparative deep sequencing.

Protein 59

Protein Antibody Engineer Scientist 59

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52